Clinical Trials

13 enrolled

CNS

Brain Neoplasms

NCT04996758 2024-12-12

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

40 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT04691388 2024-12-05

A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor

29 enrolled

NSCLC

NCT04770688 2024-08-15

AUTOMAN

Phase 1/2 Completed

25 enrolled

Adenocarcinoma of Lung, Neoplasm Metastasis

NCT05493995 2024-05-09

PAAG

66 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04271813 2024-04-23

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

30 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04967079 2024-04-23

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03906058 2023-10-25

Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

39 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04790409 2023-09-14

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

21 enrolled

Lung Neoplasms

NCT06015035 2023-08-29

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

17 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT04055792 2023-06-28

Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC

42 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03743129 2023-06-12

ALTER-L029

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05130515 2023-01-31

CC-ANNIE

6 enrolled

Gynecologic

Platinum-resistant Recurrent Clear Cell Ovarian Cancer

NCT05206656 2022-11-23

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

80 enrolled

Breast

Breast Neoplasms

NCT04507906 2022-06-28

Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC

Phase 1/2 Completed

21 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03736837 2021-03-15

ALTER-L004

60 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04002284 2020-07-29

Anlotinib in Metastatic HER2 Negative Breast Cancer

26 enrolled

Breast

Breast Neoplasms

NCT04216082 2020-01-02

A Study of Anlotinib in Subjects With Advanced Malignancy

93 enrolled

Advanced Malignancy

NCT01878448 2019-05-22

ALTN/STS

166 enrolled

Tumor-Agnostic

Neoplasms

NCT02825563 2019-05-22

A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients

22 enrolled

Advanced Cancer

NCT01874873 2019-05-21

ALTN/MTC

58 enrolled

Tumor-Agnostic

Neoplasms

NCT02586350 2019-05-21

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Phase 2/3 Completed

91 enrolled

Carcinoma, Medullary

NCT03059797 2019-05-16

Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)

120 enrolled

Small Cell Lung Carcinoma

NCT02622932 2019-04-30

Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

6 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT02388919 2017-09-18

ALTER0303

Phase 2/3 Completed

439 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01924195 2015-10-28

Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）

117 enrolled